Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)

Published By :
February 15, 2024
email icon in blackFacebook icon in blacktwitter icon in blackLinkedIn icon in black
gradient colors in orange, pink and purple

Recent News & Insights

JPM 2026: The Shift from Survival to Cautious Optimism

Featured News
·
January 20, 2026

CincyTech Announces Promotion of Sean to Vice President, Investments

Featured News
·
January 20, 2026

MY VIEW: Why Cincinnati needs to engineer serendipity

Featured News
·
December 16, 2025
More News And Insights
Subscribe TO our newsletter

Stay Up To Date With Our News & Insights

Stay informed with current news about our portfolio companies, events and industry insights.
email icon in gradient orange, pink and purple colors
You are subscribed to our newsletters
Oops! Something went wrong while submitting the form.
CincyTech is a venture capital firm that invests in innovative founders tackling the world's complex challenges. Our experienced team is fluent in the language of founders, researchers, and inventors working with deep domain expertise and market foresight. We partner early to help transform ideas into world-class companies.
2900 Reading Rd. Ste. 410 Cincinnati, OH 45206
Contact CincyTech
Twitter icon in white
Cincytech logo
HomeApproachPortfolioTeamCommunityNews & InsightsPitch Us
© 2026 Copyright - CincyTech
CareersUniversity ProgramsDisclosures
Made by 5Four Digital®